Cidara Therapeutics, Inc. (NASDAQ:CDTX) Files An 8-K Entry into a Material Definitive Agreement

On January 9, 2020, Cidara Therapeutics, Inc. (the “Company”) entered into an Investment Agreement (the “Investment Agreement”) with a certain affiliate of BVF Partners L.P. (“BVF”) and Stonepine Capital, LP, each an existing security holder of the Company (together, the “Backstop Parties”). to the Investment Agreement, the Backstop Parties agreed to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and/or Series X convertible preferred stock, par value $0.0001 per share (the “Preferred Stock”) having an aggregate value equal to the value of all shares (if any) offered but not purchased to the exercise of rights in the Company’s proposed rights offering, including any exercise of rights by the Backstop Parties (the “Rights Offering”), up to $30,000,000 (the “Backstop Commitment”). to the Investment Agreement, the Common Stock and/or Preferred Stock will be issued and sold for a subscription price of $2.51 and $25.10 per share, respectively. The Investment Agreement contains customary representations, warranties and covenants by the parties, customary conditions to closing, other obligations of the parties, and termination provisions. The closing of the transactions contemplated under the Investment Agreement are expected to occur as soon as practicable following two business days after the expiration of the Rights Offering, currently contemplated to be February 13, 2020. The offer and sale of the Common Stock and/or Preferred Stock are made in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended.

Each share of Preferred Stock is convertible into 10 shares of Common Stock. Each share will be convertible at the option of the holder at any time, provided that the holder will be prohibited from converting into Common Stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares above a conversion blocker, which is initially set at 9.99% of the total Common Stock then issued and outstanding immediately following the conversion of such shares. In the event of the Company’s liquidation, dissolution or winding up, holders of Preferred Stock will participate pari passu with any distribution of proceeds to holders of Common Stock. Holders of Preferred Stock are entitled to receive dividends on shares of Preferred Stock equal (on an as-converted basis) to and in the same form as dividends actually paid on the Common Stock or other junior securities. Shares of Preferred Stock generally have no voting rights, except as required by law.

As of January 8, 2020, BVF beneficially owned approximately 7.9% of the Company’s total outstanding shares of Common Stock (and approximately 21.1% on an as-converted basis).

The Company will not pay a fee to the Backstop Parties in connection with the Backstop Commitment, however, the Company has agreed to reimburse up to $50,000 of the Backstop Parties’ reasonable and documented legal fees and expenses in connection with the Investment Agreement and the Rights Offering.

The above description of the Investment Agreement does not purport to be complete and is qualified in its entirety by reference to the Investment Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

A summary of the rights, preferences and privileges of the Preferred Stock described above does not purport to be complete and is qualified in its entirety by reference to the Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, which is filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 21, 2018.

The information contained in Item 1.01 above is hereby incorporated by reference.

On January 10, 2020, the Company issued a press release announcing the record date and the commencement and expiration dates of the Rights Offering. A copy of the press release is filed as Exhibit 99.1 hereto.

In addition, on January 10, 2020, the Company is announcing that it now currently expects to announce topline results for the Phase 3 ReSTORE Treatment trial in late 2020.

(d) Exhibits

Cidara Therapeutics, Inc. Exhibit
EX-10.1 2 nc10007535x1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 INVESTMENT AGREEMENT This INVESTMENT AGREEMENT (this “Agreement”),…
To view the full exhibit click here

About Cidara Therapeutics, Inc. (NASDAQ:CDTX)

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease.